Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

School disruption, 'long COVID,' all factors in choice to vaccinate young kids: Tam

09/24/2021 | 04:41pm EDT

OTTAWA — When most parents decided to have kids, they probably thought some of their bigger parenting decisions would be about sleep-training, extracurricular activities or the right age to get a phone.

Few probably thought ahead to the best way to protect their kids from a global pandemic that shows no signs of slowing down after nearly a year and a half.

Soon parents might get to decide whether to vaccinate their young children against COVID-19, and according to Canada's top doctor they'll have to consider more than just the safety data.

"It is a complex set of factors," Dr. Teresa Tam, the said chief public health officer, said in a news briefing Friday.

There are no COVID-19 vaccines approved for use in children under 12 in Canada right now, but Pfizer announced earlier this week positive results in its trial for kids aged five and up.

The company said the Pfizer-BioNTech vaccine was safe, well tolerated and showed robust neutralizing antibody responses in kids aged five to 11, with results for children six months to five years old expected as early as later this year.

Once the company submits its findings to the government, Health Canada and the National Advisory Committee on Immunization will look carefully to determine if the vaccine is safe and effective for children.

But with the virus posing a smaller risk of serious illness and death in children, Dr. Nazeem Muhajarine expects parents to have more trepidation about vaccinating their kids than they did getting the shot themselves.

The same is true of long-standing routine vaccines that babies have been getting for many years, said Muhajarine, a professor of community health and epidemiology at the University of Saskatchewan.

"If you extrapolate from that to COVID-19 vaccines, I think there will be an even greater concern among some parents about getting their kids inoculated against COVID-19," he said in an interview Friday.

He said parents should consider other factors when weighing the risks and benefits of the vaccine, including the unknown effects of "long COVID."

"Some kids have shown symptoms and signs and challenges, including cognitive challenges, months and months after that initial recovery," he said. "I think we don't know much about long COVID, and we have to keep that in mind."

Rare incidents of serious illness and even death in kids can also become more common as the virus spreads through the population, Tam warned parents.

"We will see children in the hospitals, as well as some rare but serious cases, and the numbers of those can be significant if there's a lot of viral activity," she said.

In Ontario, kids under 11 years old accounted for more than 20 per cent of new COVID-19 cases in the province over the last two days.

That's up from just 12.6 per cent in the last week of August.

Parents and policy-makers will also have to consider which option is most likely to keep kids in schools, Tam said.

In Britain, the Joint Committee on Vaccination and Immunisation (JCVI) could not recommend universally vaccinating healthy kids age 12 to 15 on health grounds alone, because the margin of benefit was small, and there was evidence of a link to extremely rare cases of myocarditis — an inflammation of the heart.

In Canada there have been 774 reported instances of myocarditis and pericarditis, inflammation of the membrane around the heart, as of Sept. 17, out of 54 million vaccines administered so far.

Tam said government agencies are watching the situation carefully because though instances of myocarditis after vaccination are rare, they appear more commonly in young adults.

"This has got to be weighed against significant social, educational, developmental and mental health impacts on children for missing schools," Tam said.

Ultimately the U.K.’s four chief medical officers opted to offer vaccines to that age group anyways, in part because of the importance of kids being able to stay in their classrooms.

The National Advisory Committee on Immunization and the Public Health Agency of Canada will provide more official advice when they receive and analyze the safety and efficacy data from Pfizer and other vaccine manufacturers.

This report by The Canadian Press was first published Sept. 24, 2021.

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

All news about PFIZER, INC.
05:23pPFIZER : States can reserve COVID-19 shots for younger kids next week
02:55pFDA panel recommends J&J COVID-19 booster for all recipients who got first shot
02:13pMODERNA : COVID SCIENCE-Statins may slightly lower COVID-19 death risk; using a different ..
01:40pPFIZER : FDA panel endorses booster shot for J&J COVID-19 vaccine
01:11pMODERNA : U.S. FDA delays decision on Moderna's COVID-19 vaccine for adolescents - WSJ
01:02pPFIZER : FDA panel takes up tough questions on J&J COVID-19 boosters
11:51aMODERNA : U.S. FDA advisers to vote on J&J COVID-19 vaccine booster
11:07aTHE LATEST : Pfizer seeks European OK for child vaccines
11:02aPFIZER : BioNTech ask EU agency to OK vaccine for kids 5-11
10:55aPFIZER : BioNTech Makes European Medicines Agency Submission of Data Focusing COVID-19 Vac..
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 101 M - -
Net income 2021 18 457 M - -
Net Debt 2021 29 308 M - -
P/E ratio 2021 12,3x
Yield 2021 3,80%
Capitalization 234 B 234 B -
EV / Sales 2021 3,24x
EV / Sales 2022 3,70x
Nbr of Employees 78 500
Free-Float 59,3%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 41,49 $
Average target price 45,72 $
Spread / Average Target 10,2%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.13.20%233 631
JOHNSON & JOHNSON2.49%421 487
ROCHE HOLDING AG15.58%336 383
NOVO NORDISK A/S51.58%230 493
MERCK & CO., INC.-4.24%198 283